Mechanisms of action of a dual Cdc7/Cdk9 kinase inhibitor against quiescent and proliferating CLL cells

Molecular Cancer Therapeutics

Volumn 10, Issue 9, 2011, Pages 1624-1634

  Natoni, Alessandro ^a   Murillo, Laura S ^b   Kliszczak, Anna E ^a   Catherwood, Mark A ^c,d   Montagnoli, Alessia ^e   Samali, Afshin ^b   O'Dwyer, Michael ^b   Santocanale, Corrado ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b UNIVERSITY HOSPITAL GALWAY   (Ireland)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^d BELFAST CITY HOSPITAL   (United Kingdom)

^e NERVIANO MEDICAL SCIENCES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; CD40 LIGAND; CYCLIN DEPENDENT KINASE 7; CYCLIN DEPENDENT KINASE 9; CYCLIN DEPENDENT KINASE INHIBITOR; INTERLEUKIN 4; PHA 767491; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL DIVISION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DNA REPLICATION; DNA SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 80052697285     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-1119     Document Type: Article

References (39)

1. Zenz T, Mertens D, Kuppers R, Dohner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010;10:37-50.
2. Buggins AG, Pepper CJ. The role of Bcl-2 family proteins in chronic lymphocytic leukaemia. Leuk Res 2010;34:837-42.
3. Gandhi V, Balakrishnan K, Chen LS. Mcl-1: the 1 in CLL. Blood 2008;112:3538-40.
4. Hussain SR, Cheney CM, Johnson AJ, Lin TS, Grever MR, Caligiuri MA, et al. Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity. Clin Cancer Res 2007;13:2144-50. (Pubitemid 46649884)
5. Saxena A, Viswanathan S, Moshynska O, Tandon P, Sankaran K, Sheridan DP. Mcl-1 and Bcl-2/Bax ratio are associated with treatment response but not with Rai stage in B-cell chronic lymphocytic leukemia. Am J Hematol 2004;75:22-33. (Pubitemid 38040164)
6. Pepper C, Lin TT, Pratt G, Hewamana S, Brennan P, Hiller L, et al. Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood 2008;112:3807-17.
7. Awan FT, Kay NE, Davis ME, Wu W, Geyer SM, Leung N, et al. Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab. Blood 2009;113:535-7.
8. Chiorazzi N. Cell proliferation and death: forgotten features of chronic lymphocytic leukemia B cells. Best Pract Res Clin Haematol 2007;20:399-413. (Pubitemid 47250501)
9. Meads MB, Hazlehurst LA, Dalton WS. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 2008;14:2519-26.
10. Lampert IA, Wotherspoon A, Van Noorden S, Hasserjian RP. High expression of CD23 in the proliferation centers of chronic lymphocytic leukemia in lymph nodes and spleen. Hum Pathol 1999;30:648-54. (Pubitemid 29266723)
11. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 2009;114:3367-75.
12. Smit LA, Hallaert DY, Spijker R, De Goeij B, Jaspers A, Kater AP, et al. Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. Blood 2007;109:1660-8. (Pubitemid 46242110)
13. Vogler M, Butterworth M, Majid A, Walewska RJ, Sun XM, Dyer MJ, et al. Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood 2009;113:4403-13.
14. Willimott S, Baou M, Huf S, Wagner SD. Separate cell culture conditions to promote proliferation or quiescent cell survival in chronic lymphocytic leukemia. Leuk Lymphoma 2007;48:1647-50. (Pubitemid 47272820)
15. Willimott S, Baou M, Naresh K, Wagner SD. CD154 induces a switch in pro-survival Bcl-2 family members in chronic lymphocytic leukaemia. Br J Haematol 2007;138:721-32. (Pubitemid 47313210)
16. Sclafani RA, Holzen TM. Cell cycle regulation of DNA replication. Annu Rev Genet 2007;41:237-80.
17. Montagnoli A, Valsasina B, Brotherton D, Troiani S, Rainoldi S, Tenca P, et al. Identification of Mcm2 phosphorylation sites by S-phase-regulating kinases. J Biol Chem 2006;281:10281-90. (Pubitemid 43864566)
18. Ito S, Taniyami C, Arai N, Masai H. Cdc7 as a potential new target for cancer therapy. Drug News Perspect 2008;21:481-8.
19. Swords R, Mahalingam D, O'Dwyer M, Santocanale C, Kelly K, Carew J, et al. Cdc7 kinase - a new target for drug development. Eur J Cancer 2010;46:33-40.
20. Montagnoli A, Tenca P, Sola F, Carpani D, Brotherton D, Albanese C, et al. Cdc7 inhibition reveals a p53-dependent replication checkpoint that is defective in cancer cells. Cancer Res 2004;64:7110-6. (Pubitemid 39331024)
21. Tudzarova S, Trotter MW, Wollenschlaeger A, Mulvey C, Godovac-Zimmermann J, Williams GH, et al. Molecular architecture of the DNA replication origin activation checkpoint. EMBO J 2010;29:3381-94.
22. Menichincheri M, Albanese C, Alli C, Ballinari D, Bargiotti A, Caldarelli M, et al. Cdc7 kinase inhibitors: 5-heteroaryl-3-carboxamido-2-aryl pyrroles as potential antitumor agents. 1. Lead finding. J Med Chem 2010;53:7296-315.
23. Montagnoli A, Moll J, Colotta F. Targeting cell division cycle 7 kinase: a new approach for cancer therapy. Clin Cancer Res 2010;16:4503-8.
24. Ermoli A, Bargiotti A, Brasca MG, Ciavolella A, Colombo N, Fachin G, et al. Cell division cycle 7 kinase inhibitors: 1H-pyrrolo[2,3-b]pyridines, synthesis and structure-activity relationships. J Med Chem 2009;52:4380-90.
25. Menichincheri M, Bargiotti A, Berthelsen J, Bertrand JA, Bossi R, Ciavolella A, et al. First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery. J Med Chem 2009;52:293-307.
26. Vanotti E, Amici R, Bargiotti A, Berthelsen J, Bosotti R, Ciavolella A, et al. Cdc7 kinase inhibitors: pyrrolopyridinones as potential antitumor agents. 1. Synthesis and structure-activity relationships. J Med Chem 2008;51:487-501. (Pubitemid 351252277)
27. Montagnoli A, Valsasina B, Croci V, Menichincheri M, Rainoldi S, Marchesi V, et al. A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity. Nat Chem Biol 2008;4:357-65. (Pubitemid 351693995)
28. Nemeth G, Varga Z, Greff Z, Bencze G, Sipos A, Szantai-Kis C, et al. Novel, selective CDK9 inhibitors for the treatment of HIV infection. Curr Med Chem 2011;18:342-58.
29. Logue SE, Elgendy M, Martin SJ. Expression, purification and use of recombinant annexin V for the detection of apoptotic cells. Nat Protoc 2009;4:1383-95.
30. Hallaert DY, Jaspers A, Van Noesel CJ, Van Oers MH, Kater AP, Eldering E. c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches. Blood 2008;112:5141-9.
31. Yu Y, Arora A, Min W, Roifman CM, Grunebaum E. EdU incorporation is an alternative non-radioactive assay to [(3)H]thymidine uptake for in vitro measurement of mice T-cell proliferations. J Immunol Methods 2009;350:29-35.
32. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR. The BCL-2 family reunion. Mol Cell 2010;37:299-310.
33. Warr MR, Shore GC. Unique biology of Mcl-1: therapeutic opportunities in cancer. Curr Mol Med 2008;8:138-47. (Pubitemid 351516833)
34. Majello B, Napolitano G. Control of RNA polymerase II activity by dedicated CTD kinases and phosphatases. Front Biosci 2001;6:D1358-68.
35. Palancade B, Bensaude O. Investigating RNA polymerase II carboxylterminal domain (CTD) phosphorylation. Eur J Biochem 2003;270:3859-70. (Pubitemid 37193863)
36. Chen R, Keating MJ, Gandhi V, Plunkett W. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood 2005;106:2513-9. (Pubitemid 41510827)
37. Chen R, Wierda WG, Chubb S, Hawtin RE, Fox JA, Keating MJ, et al. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood 2009;113:4637-45.
38. Yecies D, Carlson NE, Deng J, Letai A. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood 2010;115:3304-13.
39. Dai Y, Chen S, Pei XY, Ramakrishnan V, Wang M, Orlowski R, et al. Targeting CDK9 dramatically potentiates ABT-737-induced apoptosis in human multiple myeloma cells through a Bim-dependent mechanism. Blood 2008;114:297.